Redefining the Fight Against MYC-Driven Cancers
Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. We have been formed to commercialise the discoveries emerging from China’s prestigious J. Michael Bishop Institute of Cancer Research.
Anticancer Bioscience (ACB) is a biotechnology company developing clinical-stage cancer therapies based on MYC synthetic lethality (MYC-SL). In close scientific partnership with the J. Michael Bishop Institute of Cancer Research (JMBI), ACB converts foundational discoveries in MYC biology and cellular architecture directly into therapies for aggressive solid tumors.
Founded in 2016 and headquartered in Chengdu Tianfu International BioTown, ACB focuses on MYC-driven malignancies that are poorly served by existing treatments. Its programs integrate MYC biology, cell-cycle regulation, cellular architecture, and tumor immunology to apply a structural approach to cancer treatment addressing the malignant state created by oncogenic drivers, rather than attempting to inhibit those drivers individually.
ACB was founded by Dr. Dun Yang, who worked for nearly two decades with Nobel laureate Dr. J. Michael Bishop at the University of California, San Francisco. Building on Dr. Bishop’s discovery of the cellular origin of oncogenes and his seminal contributions to MYC biology, Dr. Yang established JMBI as the scientific home of MYC-SL and Architectural Oncology—the study of cancer as a structural state—and positioned ACB as the vehicle through which this science is translated into the clinic.